Surprisingly, OSU-03012, a non-COXib structural analogue of celecoxib that is in clinical development for the treatment of lymphoma patients and has been described as PDK1 inhibitor [33,34], reproduced the effects of celecoxib (Supplementary Figure S4), suggesting that activation of AMPK might be also relevant for the effects of this compound. The gene discussed is PDK1; the disease is lymphoma.